NCCN RFP: Studies Of Trifluridine/Tipiracil For GI & Other Solid Tumors (1.7.19)

November 8, 2018
By: NCCN

The National Comprehensive Cancer Network is pleased to announce it is collaborating with Taiho Oncology, Inc. to offer a new opportunity seeking proposals for the design and performance of clinical and correlative studies of trifluridine/tipiracil, in the treatment of gastrointestinal (GI) malignancies and other solid tumors.

The intent and overall aim of this RFP is to develop innovative studies to help determine the role of trifluridine/tipiracil in the treatment of GI malignancies and other solid tumors. It is hoped that proposals submitted in response to this RFP will be useful in guiding further development of trifluridine/tipiracil. Correlative work to identify predictive markers is welcome.

ACCESS RFP ONLINE

DOWNLOAD RFP

RFP Deadline: Proposals are due by 11:59 p.m. EST on Monday, Jan. 7, 2019.

For questions regarding this RFP: E-mail Patricia Esposito with the subject line, “2019 Taiho Project.”